{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:47:16Z","timestamp":1782445636746,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bmcl.2022.128665","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T04:00:26Z","timestamp":1646712026000},"page":"128665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections"],"prefix":"10.1016","volume":"63","author":[{"given":"Satish","family":"Bhawsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128665_b0005","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.327.7425.1209","article-title":"Recent developments in \u03b2-lactamase and extended spectrum \u03b2-lactamase","volume":"327","author":"Samaha-Kfoury","year":"2003","journal-title":"Br Med J"},{"issue":"1\u20136","key":"10.1016\/j.bmcl.2022.128665_b0010","article-title":"Gram-positive resistance: challenge for the development of new antibiotics","volume":"39","author":"Baquero","year":"1997","journal-title":"J Antimicrob Chemother Suppl A"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128665_b0015.1","doi-asserted-by":"crossref","unstructured":"(a) Projan S. J, why is big pharma getting out of antibacterial drug discovery, Current Opinion in Microbiology, 6, 2003, 427-430. DOI: 10.1016\/j.mib.2003.08.003.","DOI":"10.1016\/j.mib.2003.08.003"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128665_b0015.2","doi-asserted-by":"crossref","unstructured":"(b) Projan S. J, Youngman P.J, New solutions badly needed, Current Opinion in Microbiology, 5, (2002), 463-465. DOI: 10.1016\/s1369-5274(02)00364-8.","DOI":"10.1016\/S1369-5274(02)00364-8"},{"issue":"9","key":"10.1016\/j.bmcl.2022.128665_b0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bmcl.2022.128665_b0025","article-title":"Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection","volume":"54","author":"Bhavsar","year":"2021","journal-title":"Bioorg and Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmcl.2022.128665_b0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bmcl.2022.128665_b0035","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","article-title":"DNA topoisomerase targets of fluoroquinolones: a strategy for avoiding bacterial resistance","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.bmcl.2022.128665_b0040","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.40.8.1835","article-title":"Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux mediated resistant mutants of staphylococcus aureus","volume":"40","author":"Takenouchi","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.bmcl.2022.128665_b0045","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/AAC.45.6.1649-1653.2001","article-title":"Contribution of the 8-methoxy group of gatifloxacin to resistant selectivity, target preference and antibacterial activity against Streptococcus pneumoniae","volume":"45","author":"Fukuda","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2022.128665_b0050","unstructured":"Hauser A. R, Antibiotic basics for clinicians, Wolters Kluwer N.V. information services. ISBN 9781451112214."},{"issue":"Suppl. B","key":"10.1016\/j.bmcl.2022.128665_b0055","article-title":"The effect of Moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus","volume":"31\u201337","author":"Schedlezky","year":"1999","journal-title":"J Antimicrob Chemother 43"},{"issue":"5","key":"10.1016\/j.bmcl.2022.128665_b0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/45.5.583","article-title":"R, Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones","volume":"45","author":"Pestova","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2022.128665_b0065","doi-asserted-by":"crossref","unstructured":"Beyer R, Pestova E, Millichap J. J, Stosor V, Noskin G. A, Peterson L. R, A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux, Antimicrob Agents Chemother, 44, 3, (2000), 798-801. DOI: 10.1128\/AAC.44.3.798-801.2000.","DOI":"10.1128\/AAC.44.3.798-801.2000"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128665_b0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.44.2.304-310.2000","article-title":"Antipneumococcal activities of gemifloxacin compared to those of nine other agents","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2022.128665_b0075","unstructured":"Gupte S. V, Deshpande P. K, Patel M. V, de\u2019Souza N. J, WCK 1152 and WCK 1153, Triple Targeting 7-Substituted Aminopiperidine Fluoroquinolones, interscience Conference on Antimicrobial Agents and Chemotherapy, 2003 poster, F-434."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128665_b0080","first-page":"54","article-title":"Safety of fluoroquinolones: an update","volume":"13","author":"Mandell","year":"2002","journal-title":"Can J Infect disease"},{"key":"10.1016\/j.bmcl.2022.128665_b0085","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1021\/jm030272n","article-title":"Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens","volume":"46","author":"Hu","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128665_b0090","unstructured":"de\u2019Souza N. J, Gupte S. V, Deshpande P. K, Patel M.V, Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Poster No 432, and 433."},{"key":"10.1016\/j.bmcl.2022.128665_b0095","unstructured":"de\u2019Souza N. J, Gupte S. V, Deshpande P. K, Patel M.V, Triple targeting broad spectrum fluoroquinolone, US 7626032B2."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128665_b0100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3987\/COM-94-7009","article-title":"a convenient approach to the N-substituted amino dines, N-benzyl-5-ethenyl -3,4-dihydropyridine-2-one and N-CBz-5-ethenyl-1,2,3,4-tetrahydropyridine","volume":"41","author":"Bigogno","year":"1995","journal-title":"Heterocycle"},{"issue":"3","key":"10.1016\/j.bmcl.2022.128665_b0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0250-474X.43001","article-title":"HPLC Method for determination of enatiomeric purity of a novel respiratory fluoroquinolone: WCK 1152","volume":"70","author":"Yeole","year":"2008","journal-title":"Ind J Pharm Sci"},{"key":"10.1016\/j.bmcl.2022.128665_b0110","doi-asserted-by":"crossref","unstructured":"Wutz P. G. M, Greene's Protective Groups in Organic Synthesis, Online ISBN:9781118905074, DOI:10.1002\/9781118905074.","DOI":"10.1002\/9781118905074"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2200141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2200141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:44:01Z","timestamp":1760773441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2200141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":23,"alternative-id":["S0960894X2200141X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128665","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128665"}}